Cosciens Biopharma INC. 6-K Filing
Ticker: CSCIF · Form: 6-K · Filed: Nov 12, 2025 · CIK: 1113423
| Field | Detail |
|---|---|
| Company | Cosciens Biopharma INC. (CSCIF) |
| Form Type | 6-K |
| Filed Date | Nov 12, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Cosciens Biopharma INC. (ticker: CSCIF) to the SEC on Nov 12, 2025.
How long is this filing?
Cosciens Biopharma INC.'s 6-K filing is 3 pages with approximately 990 words. Estimated reading time is 4 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 15.7 · Accepted 2025-11-12 09:00:20
Filing Documents
- form6-k.htm (6-K) — 32KB
- ex99-1.htm (EX-99.1) — 56KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-021770.txt ( ) — 93KB
forward-looking statements
forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization. the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid Hormone (DC-PTH) programs ; the transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address the administration’s policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in which we operate. the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ab